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as myalgia, myositis, arthralgia, chronic 
fatigue, sleep disturbances, neurological 
manifestations and cognitive impairment. 
The increasing number of cases in the 
literature linking vaccine adjuvants and 
autoimmunity has helped substantiate 
this relationship [3]. For instance, there 
is evidence demonstrating a connection 
between various defined rheumatologic 
illnesses with immunizations, such as sys-
temic lupus erythematosus developing after 
the hepatitis B virus (HBV) and human 
papillomavirus vaccinations. Furthermore, 
a possible association between various 
autoimmune syndromes and the varicella 
and measles-mumps-rubella vaccinations 
has also been documented [4].
In the general population, autoimmune 
manifestations of a neurological nature 
following immunization have also been 
reported. These post-vaccination neuro-
logical complaints consist predominately 
of neuropathy, encephalitis, vasculitis 
and demyelination. A literature review 
showed that neuromuscular conditions, 
such as Guillain-Barre syndrome (GBS), 
myasthenia gravis, optic neuritis and 
inflammatory myopathies, have a temporal 
relationship with the HBV and hepatitis A 
vaccines as well as numerous other vac-
cines. It has also been reported that cases 
of multiple sclerosis have been triggered 
by the administration of the HBV vaccine. 
Additionally, there is a correlation between 
the cellular Bordetella pertussis portion of 
the diphtheria-tetanus-pertussis vaccine 
and increased risk of seizure. However, 
since many of these neuromuscular auto-
immune illnesses are rare in themselves, a 
direct relationship cannot be confirmed. 
i nnovations in vaccination technology have helped eradicate many diseases 
throughout the Western and developed 
worlds. During the last 50 years vac-
cines have diminished the incidence of 
once commonplace pediatric and adult 
diseases. Although vaccine technology 
is safe, non-specific reactions following 
the administration of immunizations 
sometimes occur, which typically include 
site-reaction transient flu-like symptoms. 
However, recent evidence has spotlighted 
the development of autoimmune phenom-
ena post-vaccination in sporadic cases [1]. 
These adverse reactions are thought to be 
due to associated adjuvants and foreign 
antigens. Recently, the autoimmune syn-
drome induced by adjuvants (ASIA) was 
defined, which includes related diseases 
such as the Gulf War syndrome, macro-
phage myofasciitis syndrome, siliconosis, 
and post-vaccination phenomena [2]. 
The current understanding is that vac- 
cine adjuvants play an essential role in the 
pathogenesis of autoimmunity in these 
patients. They typically consist of alumi-
num salts, which are added to help enhance 
the response of the host innate and adap-
tive immune system [2]. In a minority 
of patients, the adjuvants stimulate the 
creation of autoantibodies as well as the 
appearance of clinical symptoms such 
During the spring of 2009, an eruption 
of new influenza cases was quickly denoted 
“the swine flu.” The H1N1 vaccination was 
created for four influenza A viruses and 
its efficacy led to a reduction in H1N1 
infectivity rates and hospital admissions. 
While some H1N1 vaccines were associ-
ated with flu-like symptoms typically 4 to 
7 days post-administration, a very small 
population of patients developed more 
severe side effects, including autoimmune 
and neuroimmune phenomena.
Although the etiology of transverse 
myelitis, a rare inflammatory spinal-cord 
condition, is largely unknown, there is 
growing evidence in the literature that an 
autoimmune syndrome induced by the 
adjuvant phenomenon is responsible in 
some cases for the disease pathogenesis 
[4]. According to a recent multi-analysis 
conducted by our research team, 37 cases 
of transverse myelitis developed within one 
month post-vaccination that used various 
common immunizations [5]. Similar to the 
immune reaction of infectious diseases, 
vaccine adjuvants cause autoimmunity 
in a similar manner, including molecular 
mimicry, epitope spreading, up-regulation 
of cytokines, and polyclonal activation of B 
and T lymphocytes [5]. 
In this report, we will attempt to further 
the discussion by illustrating a case of trans-
verse myelitis 2 months post-vaccination 
with the influenza A (H1N1) immuniza-
tion. 
Patient descriPtion
A 41 year old man presented to our depa- 
rtment with headache, leg paresthesia and 
transverse myelitis, adjuvants, 
autoimmunity, immunization, 
autoimmune syndrome induced by 
adjuvants (ASIA)
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sensory loss of 2 months duration. The 
patient had been diagnosed with psoriasis 
9 years earlier and was initially prescribed 
only a topical medication to treat the skin 
lesions. His disease history is significant 
for one exacerbation 5 years after his 
original diagnosis, which manifested as an 
abrupt eruption of psoriatic lesions in the 
scalp and nails. The patient also developed 
arthritis of the hands and left foot dactylitis 
shortly thereafter. He was then treated with 
prednisone 5 mg/day and methotrexate 20 
mg/week, and has been in complete remis-
sion without any medication for the past 
2 years. 
The patient’s vaccination history was 
significant for both the influenza A 
(H1N1) and yellow fever immunizations. 
The yellow fever vaccine was administered 
16 months before onset of the initial neu-
rological symptoms. He reported myalgia, 
arthralgia, fatigue, xerostomia and non-
bilious non-blooding emesis for a period 
of 8 days post-vaccination. Two months 
before the appearance of neurological 
symptoms, he had received the influenza 
A (H1N1) vaccination and no acute 
adverse reaction occurred. Two months 
later, the patient consulted with a family 
physician due to the gradual appearance 
of an occipital headache and general-
ized fatigue. He was sent for magnetic 
resonance imaging (MRI), which demon-
strated a mild disk protrusion at the level 
of C5-C6 without spinal cord compromise. 
Cervicobrachialgia was suspected for 
which analgesics and anti-inflammatory 
medications were prescribed, resulting in 
slight amelioration of his symptoms. 
Owing to the persistence of his neuro-
logical complaints, the patient was admit-
ted to our department for further workup. 
Upon admission, he complained of con-
tinued occipital-located headache, which 
persisted throughout the day and night. 
He also complained of xerostomia without 
signs of xerophthalmia. He reported par-
esthesia of both legs with any movement 
of his neck. He denied recent trauma, 
visual disturbances, nausea, vomiting or 
recent fever. On physical examination, he 
appeared well and in no acute distress. His 
vital signs and cardiovascular and respira-
tory systems were unremarkable. His abdo-
men was soft and non-tender. Neurological 
examination was significant only for a loss 
of transient vibratory sensation in his 
thighs bilaterally. He denied neck stiffness 
and displayed no meningeal signs. 
His blood cell count and liver and 
muscle enzymes were within normal lim-
its. Protein electrophoresis, electrophoresis 
of immunoglobulins and complement 
were within the normal reference range. 
Furthermore, serological testing was nega-
tive for rheumatoid factor, antinuclear anti-
bodies (including specific testing for anti-
RNP, Sm, Ro, La), anti-DNA, anticardio-
lipin antibodies (immunoglobulins G and 
M), lupus anticoagulant, and perinuclear 
and cytoplasmic antineutrophil cytoplasmic 
antibodies (p-ANCA and c-ANCA). Tests 
for Mycobacterium tuberculosis, including 
the purified protein derivative test and 
polymerase chain reaction, were normal. 
Enzyme-linked immunosorbent assay 
(ELISA) for anti-aquaporin 4 antibodies 
was also negative. A lumbar puncture was 
performed and cerebral spinal fluid (CSF) 
demonstrated normal appearance, cytology 
and biochemistry. CSF testing for VDRL, 
parasitic and viral serologies were nega-
tive, and electrophoresis gamma was 18% 
(7–14%) with absent monoclonal bands. 
A spinal cord MRI highlighted three 
medullar hyperintense lesions on T2 
that enhanced after gadolinium use: two 
appeared at D1 and D5, which were at the 
left paramedian region, and did not exceed 
0.5 cm in diameter, and one was at the level 
of D7, reaching 1 cm in diameter, also left 
paramedian. A brain MRI demonstrated 
no abnormalities. Further neurological 
evaluation was normal, including elec-
troneuromyography of all four limbs and 
visual evoked potential. 
The patient was diagnosed with trans-
verse myelitis based on clinical symptoms 
and the MRI findings. He was treated 
initially with three pulses of intravenous 
methylprednisolone 1000 mg. Additionally, 
oral corticosteroids and azathioprine were 
administered as maintenance therapy. 
Approximately 3 months after admission, 
he experienced a total remission of all neu-
rological symptoms. At follow-up 7 months 
after admission to our department, the 
patient’s brain and spinal cord MRIs dem-
onstrated no signs of demyelinating lesions. 
comment
We describe a 41 year old man who expe-
rienced leg paresthesia and sensory loss 
2 months after immunization with the 
influenza A H1N1 vaccination. The clini-
cal laboratory and imaging results were 
compatible with the diagnosis of trans-
verse myelitis, while a direct etiology was 
not defined. The patient was successfully 
treated with corticosteroids and azathio-
prine. The fact that the symptoms appeared 
2 months after the vaccination suggests an 
immune mediated reaction to the immuni-
zation, or ASIA syndrome [5]. The patient’s 
background of psoriatic arthritis, together 
with a history of inflammatory reaction 
following yellow fever immunization, may 
suggest an autoimmune tendency. 
The seasonal influenza virus may 
cause neurological symptoms; the inci-
dence of encephalopathy and delirium 
during infection is as high as 1:100,000 
especially among children. Nevertheless, 
a small minority of patients may suffer 
from neurologic-autoimmune phenom-
enon following the H1N1 vaccination. 
The most notable example of an influenza 
vaccine causing an autoimmune process is 
that of Guillain-Barre syndrome after the 
induction of the Influenza A/New Jersey 
vaccination in 1976. The incidence of GBS 
was significantly higher in the population 
receiving the vaccination. A recent meta-
analysis of the relation between GBS and 
the influenza A (H1N1) 2009 monovalent 
inactivated vaccine showed a slightly 
increased risk of the condition developing. 
In a large Swedish cohort of one mil-
lion patients receiving the Pandremrix 
Influenza A (H1N1) monovalent-adju-
vanted vaccine, there was an increase in the 
risk of Bell’s palsy and various paresthesias. 
Since the 2009 H1N1 pandemic, there has 
also been a reported spike in the incidence 
of narcolepsy in Europe that may be associ-
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ated with the swine-influenza vaccination. 
This finding reinforces the view of some 
researchers in the field of sleep disorders 
that the impairment of orexin-producing 
neurons in the brains is associated with an 
autoimmune process.
Additionally, there are at least three case 
reports in the literature that describe epi-
sodes of transverse myelitis that occurred 
after H1N1 immunization. In one report, 
a 44 year old man suffered from fever and 
various neurological symptoms, includ-
ing right leg paresthesia, one month after 
receiving the influenza A (H1N1) vaccine. 
The patient demonstrated hyperdense MRI 
lesions at the level of C6 and C7 and was 
diagnosed with TM. In South America, 
a second report chronicled a 52 year old 
woman who developed a thoracic intra-
medullary lesion one week after immuni-
zation with a H1N1-trivalent vaccine with- 
out evidence of other causes of the epi-
sode. A third case of transverse myelitis 
was described after the administration of 
the monovalent A (H1N1) nasal influenza 
vaccine in a 27 year old woman. 
In conclusion, the induction of trans-
verse myelitis post-immunization is plau-
sible in view of the increasing frequency 
of case reports in the medical literature 
demonstrating this phenomenon as well as 
the growing biological evidence of a post-
vaccination autoimmune pathogenesis.
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The Hippo pathway limits cell proliferation by inhibiting the 
activity of the transcriptional coactivator YAP. In contrast, cell pro- 
liferation is stimulated by the binding of growth factors to tyrosine 
receptor kinases, such as the binding of neuregulin to ERBB4. 
Neuregulin binding also triggers the cleavage of ERBB4. Haskins 
et al. found that a fragment containing the intracellular domain 
of ERBB4 interacted with and activated YAP. Breast cancer cell 
migration induced by neuregulin was blocked by knocking down 
YAP. Thus, ERBB4 could promote tumor aggressiveness both 
through receptor tyrosine kinase signaling and by stimulating YAP. 
Sci Signal 2014; 7: ra116 and pe29 
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The unprecedented 2014 epidemic of Ebola virus disease 
(EVD) has prompted an international response to accelerate 
the availability of a preventive vaccine. A replication-defective 
recombinant chimpanzee adenovirus type 3-vectored ebola virus 
vaccine (cAd3-EBO), encoding the glycoprotein from Zaire and 
Sudan species that offers protection in the non-human primate 
model, was rapidly advanced into phase 1 clinical evaluation. 
Ledgewood et al. conducted a phase 1, dose-escalation, open-
label trial of cAd3-EBO. Twenty healthy adults, in sequentially 
enrolled groups of 10 each, received vaccination intramuscularly 
in doses of 2x1010 particle units or 2x1011 particle units. Primary 
and secondary end-points related to safety and immunogenicity 
were assessed throughout the first 4 weeks after vaccination. In 
this small study, no safety concerns were identified; however, 
transient fever developed within 1 day after vaccination in 
two participants who had received the 2x1011 particle-unit 
dose. Glycoprotein-specific antibodies were induced in all 20 
participants; the titers were of greater magnitude in the group 
that received the 2x1011 particle-unit dose than in the group 
that received the 2x1010particle-unit dose (geometric mean titer 
against the Zaire antigen, 2037 vs. 331; P = 0.001). Glycoprotein-
specific T cell responses were more frequent among those who 
received the 2x1011 particle-unit dose than among those who 
received the 2x1010 particle-unit dose, with a CD4 response in 10 
of 10 participants versus 3 of 10 participants (P = 0.004) and a 
CD8 response in 7 of 10 participants versus 2 of 10 participants 
(P = 0.07). Reactogenicity and immune responses to cAd3-
EBO vaccine were dose dependent. At the 2x1011 particle-unit 
dose, glycoprotein Zaire-specific antibody responses were 
in the range reported to be associated with vaccine-induced 
protective immunity in challenge studies involving non-human 
primates. Clinical trials assessing cAd3-EBO are ongoing. 
N Engl J Med 2014; DOI: 10.1056/NEJMoa1410863
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